• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Distribution and ecological risk assessment of typical antibiotics in the surface waters of seven major rivers, China?
  Environ. Sci.: Processes Impacts, 2021,23, 1088-1100
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Recent Advances in Cyclobutane-1,3-diamine Dihydrochloride (CAS: 1314772-13-8) Research: A Comprehensive Review

Cyclobutane-1,3-diamine dihydrochloride (CAS: 1314772-13-8) has emerged as a critical compound in the field of chemical biology and pharmaceutical research due to its unique structural properties and versatile applications. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. Recent studies have highlighted its role as a key intermediate in the development of novel drug candidates, particularly in the areas of antiviral and anticancer therapies.

The compound's rigid cyclobutane ring structure, combined with its diamine functionality, makes it an attractive scaffold for drug design. Recent synthetic methodologies have improved the efficiency and yield of Cyclobutane-1,3-diamine dihydrochloride production, enabling more extensive exploration of its pharmacological properties. Advanced techniques such as asymmetric synthesis and catalytic hydrogenation have been employed to achieve high enantiomeric purity, which is crucial for its application in chiral drug development.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated the compound's potential as a modulator of various biological pathways. Notably, its derivatives have shown promising activity against viral proteases, particularly in the context of emerging RNA viruses. The dihydrochloride salt form enhances the compound's solubility and bioavailability, making it particularly suitable for pharmaceutical formulations. Mechanistic studies have begun to elucidate its interactions with specific molecular targets, providing a foundation for structure-activity relationship (SAR) optimization.

From a therapeutic perspective, several research groups have reported the development of Cyclobutane-1,3-diamine dihydrochloride-based compounds with enhanced efficacy and reduced toxicity profiles. These include novel kinase inhibitors and DNA-intercalating agents that show potential in oncology applications. The compound's ability to serve as a building block for peptidomimetics has also been exploited in the design of protease-resistant therapeutic peptides. Clinical translation of these findings remains an active area of investigation, with preliminary pharmacokinetic studies showing favorable absorption and distribution characteristics.

The safety profile of Cyclobutane-1,3-diamine dihydrochloride has been systematically evaluated in recent toxicological studies. Acute and subchronic toxicity assessments indicate a favorable safety margin at therapeutic doses, though further long-term studies are warranted. Regulatory considerations for its use in drug development are currently being addressed, with particular attention to Good Manufacturing Practice (GMP) compliance for clinical-grade material production.

Looking forward, the research community anticipates continued innovation in the application of Cyclobutane-1,3-diamine dihydrochloride. Emerging areas of interest include its incorporation into targeted drug delivery systems and its use in the development of covalent inhibitors. The compound's versatility suggests it will remain a valuable tool in medicinal chemistry for the foreseeable future, with potential applications extending beyond current therapeutic areas into neurological disorders and antimicrobial resistance challenges.

• 1082681-41-1((1r,3r)-1,3-cyclohexanediamine Hydrochloride (1:1))
• 590-88-5(butane-1,3-diamine)
• 6291-01-6(Cyclobutanamine hydrochloride)
• 44391-42-6((3R)-butane-1,3-diamine)
• 91301-66-5(Cyclobutane-1,3-diamine)
• 498532-32-4(cis-cyclohexane-1,3-diamine;dihydrochloride)
• 2516-34-9(Cyclobutanamine)
• 25139-83-7((3S)-butane-1,3-diamine)
• 38780-37-9(Cyclobutanamine;platinum(2+);dichloride)
• 63591-57-1(cis-Cyclopentane-1,3-diamine dihydrochloride)